Although Judeline drugs can effectively promote gonadal hormone release, but easy to be characteristic of gastrointestinal peptide enzymatic degradation, the oral invalid, clinical often need injection. Because some diseases need to be administered for a long time, this provides an opportunity for innovative dosage forms.

Such as slow release microspheres, the world's first public offering of the French company Ipsen development of sustained release microspheres, released in 1986. The technology of sustained-release microspheres is that the drug is encapsulated in the microspheres carrier, and the drug is released slowly by subcutaneous or muscle, so as to change the process of in vivo transport and prolong the time of the drug delivery. Leuprorelin also used microspheres technology.

Implant sustained-release effect, not only reduces the trouble of continuous use, also provides the convenience for contraception or treatment of cancer and chronic diseases such as Judeline drugs.

The implants were divided into non injectable implants and injectable implants. Non injectable implant is implanted into the human body by surgery, and the drug can be released slowly and evenly over a long period of time. An injectable implant is a mixture of the drug and PLGA, which is then extruded into a strip by a porous device, cut into a certain length, and sterilized into a special disposable syringe. Direct subcutaneous or intramuscular injection of the drug, with the release of the material degradation and play a long-term role. The injectable implant does not need to be surgically implanted or removed, as is the non injectable implant. The computer controlled infusion system can be used for a long time and accurate administration. It is a safe and effective way to treat chronic diseases.

Long-acting formulation

ENDO treatment of prostate cancer drug histrelin VANTAS usage is annually given subcutaneous implants can be stable, so as to keep the long-term suppression of testosterone, castration level, so that the palliative treatment of advanced prostate cancer can be achieved. It uses Valera's Hydron (hydron) implantation of patented technology, so that the histrelin continuous administration for 12 months.

Another histrelin 2007 ENDO approved drug SupprelinLA, clinically used in the treatment of central precocious puberty. It is through the subcutaneous implantation of micro plate lasts 1 years slow release of histrelin and suppression of pituitary gonadotropin secretion, depress puberty. The test results show that the histrelin with arm subcutaneous implantation of a one-year 50mg for the treatment of central precocious puberty is very effective, and has the advantages of avoiding repeated injections of medication and dose adjustment.

Of course, also do goserelin implants ZOLADEX fast AstraZeneca in China, with a 3.6mg per month and once every March 10.8mg two specifications, in 2015 global sales of $816 million.

Due to their unique physical and chemical properties, LHRH drugs are destined to be innovative in the development of drugs, but also to make new formulations, new technologies to achieve rapid development. The new technology in decreasing toxicity, increase patient compliance at the same time, it also made the legend of Alarelin polypeptide drugs.